Hero Finding
Side-effect profile drives roughly 42% of patient treatment choice, about 1.6 times the weight of efficacy.
A serious systemic safety signal is effectively disqualifying: avoiding it proved worth roughly 49 percentage points of efficacy in the choice model, more than the entire 20-to-50% efficacy range tested. Preference-based segmentation of the choice data confirms the hierarchy: safety-first is the largest patient segment, ahead of efficacy-driven and speed-and-convenience.
Preference-based segmentation of the six-task choice exercise · % of N=301 patients
Key Findings
What the patient record surfaced.
Six signals reframed the unmet-need picture and defined what a new therapy must look like to win switches, each grounded in quant + qual data from the same 301 patients.
The treated market is still symptomatic, and the burden reads through to daily life.
Across all 301 patients, 63% reported residual itch that remains noticeable or worse on their current treatment, and only 4% called their itch completely resolved. Classified on residual itch and lesions together, 31% of the sample qualified as responders to current therapy, 62% as partial responders, and 7% as non-responders. 54% rated the disease's current quality-of-life impact at 7 or higher out of 10 despite being on treatment, with self-confidence (74%), sleep (72%), and mental health (66%) the most affected areas.
Residual burden converts directly into switching appetite.
Of the 211 patients currently on an advanced therapy, only 5% ruled out switching. Better itch control led every switching driver at 67%, ahead of better skin clearance (54%) and faster onset (49%). The pattern sharpened by response status: 75% of partial responders cited itch control as a switch driver against 51% of responders, a statistically significant gap that marks partial responders, the majority of the treated market, as the switch-ready core.
Side-effect profile outweighs efficacy in the treatment decision.
The six-task choice exercise decomposed each attribute's share of the decision. Side-effect profile carried roughly 42% of the weight, about 1.6 times efficacy, with speed of onset and dosing route trailing. Trade-off modeling made the hierarchy concrete: avoiding a serious systemic safety signal was worth roughly 49 percentage points of efficacy, more than the entire 20-to-50% efficacy range tested.
Efficacy behaves as a credibility threshold in the choice data.
Patient preference turned positive only at around 40% clearance, so efficacy works as a bar to clear rather than a maximization target. Onset within days was clearly preferred to weeks. Preference-based segmentation of the choice data found three patient types: safety-first (43%), efficacy-driven (33%), and speed-and-convenience (24%).
Injection comfort follows the route patients already use.
Two-thirds (67%) of current biologic users are very comfortable self-injecting, against 33% of oral JAK users and 30% of topical-only patients, and 23% of topical-only patients are very uncomfortable. In the choice model, route leaned mildly toward oral but sat subordinate to safety. Comfort with a route follows experience with it: an injection-naive segment exists for an oral option to unlock, while an injectable competes on safety among patients already at ease with the pen.
The unescalated majority is held back by addressable barriers.
Among topical-only patients, the market's unescalated majority, barriers to advanced therapy were led by side-effect concerns (43%), cost and coverage (37%), and a doctor who has never suggested one (37%), with fear of injections cited by 23%. The base is small (n=30, capped at 10% by design), so the read is directional. Each barrier reads to positioning, access strategy, or clinician education rather than product performance.
The unmet need clinicians rated low is concentrated inside the treated market itself.
Going in, the client's professional research pointed the other way: with five to six advanced therapies available, clinicians perceived remaining unmet need as relatively low, and only around 15 to 20% of clinically eligible patients ever escalate to advanced systemic therapy. The patient record inverted the picture. 63% of treated patients still report noticeable residual itch, only 4% call their itch completely resolved, and 95% of patients on advanced therapy are open to switching. The market prescribers describe as well-served is, from the patient side, a switch-ready population still carrying daily symptom burden.
Some medications are crazy because it will clear up eczema, but it will give you cancer, or it will give you a eye disease, or, you know, the side effects are crazy. Like, sometimes the ends don't justify the means.
Patient · moderate AD, current biologic user
Study Design
N=301US adults with moderate-to-severe atopic dermatitis
Four treatment cohorts
AI-moderated quant + qual interviews
Six-task choice-based conjoint
Recruiting screened on diagnosis source, severity, duration, and body surface area, and terminated clinically implausible treatment regimens. 4,504 interview records opened across an 11-day field window resolved to 301 verified completes from three recruiting providers, with per-interview QC scoring and removal review. The topical-only cell was capped at 10% by design.
Sample by segment
Mix
What the guide covered
- Journey from symptom onset through diagnosis and brand choice
- Residual symptom burden on current treatment: 0-10 severity scales for itch, lesions, and skin pain with rating-triggered probes
- Quality-of-life and life-area impact measures
- Treatment history across a 14-row usage matrix: current, past, and never used
- Switching drivers with ranking, plus looped discontinuation probing on the most recently abandoned therapy
- Six choice-based conjoint tasks over four attributes: side-effect profile, efficacy, speed of onset, dosing route
- Barriers to escalation among topical-only patients
Who qualified
- US adults with physician-diagnosed moderate-to-severe atopic dermatitis
- Diagnosed at least one year prior to screening
- 10% or more body surface area involvement
- Quotas across biologic, oral JAK inhibitor, lapsed advanced-therapy, and topical-only cohorts
Crosstab · Route Comfort
Injection comfort by current treatment class.
Share of each treatment cohort very comfortable and very uncomfortable with self-injection. Comfort follows the route patients already use, which sizes the population an oral option can reach and the population an injectable must win on safety.
| Biologic users (n=130) | Oral JAK users (n=81) | Topical-only (n=30) | |
|---|---|---|---|
| Very comfortable self-injecting | 67% | 33% | 30% |
| Very uncomfortable self-injecting | 2% | 5% | 23% |
Very comfortable · biologic significant against both other classes · Topical-only n=30 · capped at 10% by design · Comfort tracks the route in current use
Voice of the Patient
What patients actually said.
Verbatim excerpts from the interview record, selected to span the four treatment cohorts and the range of switch positions.
“The itching is the most maddening part of this condition. Period. I can handle looking kinda gross here and there, whatever, but the itching is what drives me nuts the most. It's just you know, it's constant. It's horrible.”
“It affects my sleep because the feeling of discomfort will creep into my dreams and make calming rest very difficult.”
“Fewer side effects is the single most important fact to me because I want to be reassured that the treatment I am using is safe and will not further harm my health. Knowing that it has fewer side effects gives me greater peace of mind.”
“If the itching was under control, I wouldn't have leathery skin. So the itching is the main issue. Itching is what keeps me awake. The itching is what causes all of the irritation and the pain.”
“It's just not as easy as a pill. So there's just no convincing me otherwise. But if it's absolutely necessary and I do trust my doctor, and we'll talk about it. If that's the way to go, then I will just accept it. It's just a harder hill to climb for me.”
“My doctor has not said that I am so severe that we try injections.”
Implications · what the evidence supports
Four readings from the research.
What the evidence supports for launch positioning, grounded in the choice model and the patient record.
Safety is the positioning ground a differentiated entrant can own.
Side-effect profile carries roughly 42% of the treatment decision, about 1.6 times the weight of efficacy, and 43% of patients decide on safety first. A safety-differentiated profile competes on the attribute patients care about most, provided efficacy clears the roughly 40% credibility threshold.
Partial responders are the switch-ready core of the treated market.
62% of the sample classifies as partial responders to current therapy, and 75% of them cite better itch control as a switch driver against 51% of full responders, a statistically significant separation. Residual-symptom relief, itch above all, is the entry story the data supports for a new agent.
Route strategy is segment strategy, because route preference is learned.
Comfort with self-injection tracks the route in current use: 67% of biologic users are very comfortable against 30% of topical-only patients. An oral option opens the injection-averse topical-only and oral JAK cohorts, while an injectable competes among biologic-experienced patients who are already comfortable injecting and choose on safety.
The unescalated majority is reachable through positioning, access, and clinician education.
The barriers topical-only patients name, side-effect concerns (43%), cost and coverage (37%), and a doctor who has never suggested advanced therapy (37%), sit in communication and access rather than in product performance. On this read, the escalation gate opens without additional clinical differentiation, though the n=30 base keeps it directional.
Signals the data flagged
- 95% of advanced-therapy patients open to switching, with better itch control the top driver at 67%
- A 43% safety-first segment, the largest of the three preference types
- Patient preference turns positive only above roughly 40% clearance
- Avoiding a serious systemic safety signal is worth roughly 49 points of efficacy, more than the full range tested
Risks the data surfaced
| A serious systemic safety signal is effectively disqualifying at any tested efficacy | High |
| Efficacy below the roughly 40% clearance threshold reads as non-credible to patients | High |
| Injection aversion caps injectable reach in the unescalated topical-only cohort | Med |
| Cost and coverage gate escalation for topical-only patients | Med |
| Topical-only read is directional · n=30 capped by design | Low |